The innovative in-vitro device for non-invasive identification of organ rejection in heart-transplant patient
A complete patient monitoring procedure from blood-sampling to the final report

INNOGRAFT HS core innovation


Liquid biopsy

NON-INVASIVE_Rejection causes a dispersion of free DNA in the bloodstream of the patient: the greater is this quantity, the more serious the rejection. InnoGraft needs only a blood sample to determine this correlation

cfDNA technology

cfDNA technology

PERSONALIZED_Organ transplantation brings donor DNA (cfDNA) into the patient. Due to this evidence InnoGraft Reagent Kit uses donor’s DNA as biomarker of rejection

Artificial Intelligence

Artificial Intelligence

SMART_The algorithm quantifies the donor cfDNA in the recipient blood and correlate it to rejection, thanks to our Artificial Intelligence, trained with Deep-Learning tools

>100.000

Patients transplanted every year

>7.000

Heart tranplants every year

>200.000

Invasive procedures every year

>290.000

NON-invasive procedures/year potentially doable

INNOGRAFT is the key to innovate the surveillance approach and to radically improve post-transplant management.

Insight InnoGraft Projects


Innograft components

The device is made of two components, the Reagent Kit (DNA test panel) and the Interpretation Software (cloud-based algorithm for analysis and automatic report-creation) both designed by MWG.

Global expansion

The solution is based on a lean and scalable business model: the analysis of the blood sample is performed in the transplant center with the reagent kit, the data are analysed by cloud-based proprietary algorithm.

Future application

cfDNA as a bio-marker is not organ dependent: it can be used for monitoring of rejection in all solid organs post-transplant. MWG will develop InnoGraft suites to improve the life of all transplanted patients.

Improving life

A non-invasive solution for rejection surveillance will dramatically improve the quality of life of the patients and reduce social costs. Our powerful vision to find a concrete answer to the medical need is becoming a reality with InnoGraft.

Predictivity

Tissue biopsy can identify rejection when organ damage exceeds a certain degree. InnoGraft HS, with its continuous nature (blood-analysis), promises to be more sensible than the biopsy, and to identify early rejection.

Literature perspective

What the Experts Say